Combined General Meeting of June 24, 2024
Combined General Meeting of June 24, 2024
Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.
2024年6月7日，法國巴黎和美國馬薩諸塞州劍橋/ACCESSWIRE/——臨床階段生物技術公司Biophytis SA (Euronext Growth Paris:ALBPS), (“Biophytis”或“公司”)，專注於治療與年齡相關的疾病的治療方案的開發，將於2024年6月24日下午2點在Paris 75005 Jussieu 4號 Herpin講堂舉辦其聯合大會(CGM)。
The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 59 of May 15, 2024.
會議通知，包括議程、草案決議和出席的條款和條件，已發佈在2024年5月15日的Bulletin des Annonces Légales Obligatoires (BALO)第59號中。
Information and preparatory documents for this General Meeting, including the voting form and the access map, are available on the Company's website ().
本次股東大會的相關信息和準備文件，包括投票表和進入地圖，都可在公司網站上 ().
Shareholders are strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via the secure online platform VOTACCESS.
強烈鼓勵股東提前參與投票，通過郵寄 (i)、指定會議主席爲代理人 (ii)，或通過安全的在線平台 VOTACCESS 投票(iii) 參與 CGM。代理投票或者郵寄投票需在股東大會前三天提交 (即 2024 年 6 月 21 日前) 在線投票需在股東大會前一天提交 (即 2024 年 6 月 23 日前)。
Votes must be submitted no later than three days before the general meeting (i.e. June 21, 2024) for proxy votes or postal votes and the day before for proxy votes or postal votes via VOTACCESS (i.e. June 23, 2024).
強烈鼓勵股東提前參與投票，通過郵寄 (i)、指定會議主席爲代理人 (ii)，或通過安全的在線平台 VOTACCESS 投票(iii) 參與 CGM。代理投票或者郵寄投票需在股東大會前三天提交 (即 2024 年 6 月 21 日前) 在線投票需在股東大會前一天提交 (即 2024 年 6 月 23 日前)。
****
****
About BIOPHYTIS
關於Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The Company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on OTC market (Ticker: BPTSY - ISIN: US09076G4010). For more information, visit
Biophytis SA 是一家專門從事研發老年相關疾病藥物候選品的臨床階段生物技術公司。 BIO101（20-羥基蛻皮激素）是我們的主要藥物候選品，是一種小分子化合物，正在開發針對肌肉（肌肉萎縮症，階段3待就緒和杜興氏肌營養不良），呼吸系統（Covid-19階段2-3已完成）和代謝疾病（肥胖症，階段2即將開始）的治療方案。公司總部設在法國巴黎和馬薩諸塞州劍橋市。公司的普通股票上市交易於歐洲納斯達克(Euronext Growth)上（代碼: ALBPS - ISIN: FR0012816825），美國存托股曾上市於OTC市場 (代碼:BPTSY - ISIN: US09076G4010)。欲了解更多信息，請訪問
Forward-looking statements
前瞻性聲明 本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明（包括與我們社會、環境和其他可持續性目標有關的聲明）的非歷史事實的前瞻性聲明，是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的，或者必須披露在我們向證券交易委員會（“SEC”）或其他監管機構的備案中。此外，歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設，在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設，並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新聞稿包含前瞻性聲明。前瞻性聲明包括所有非歷史事實陳述。 在某些情況下，您可以通過使用“前景展望”，“相信”，“期望”，“潛力”，“繼續，”，“可能”，“將” ，“應該”，“可能”，“尋求”，“預測”，“打算”，“趨勢”，“計劃”，“估計”，“預計” 或這些詞的負面版本或其他可比較的詞語來識別這些前瞻性陳述。 這類前瞻性聲明是基於Biophytis認爲合理的假設。然而，不能保證這些前瞻性陳述中包含的陳述將得到證實，這些陳述還可能受到各種風險和不確定性的影響。此 新聞稿中包含的前瞻性聲明也可能受到 Biophytis 尚未了解或目前不認爲重要的風險的影響。因此，存在或將存在重要因素可能導致實際結果或成果與這些聲明中指示的結果存在重大差異。此外，請參閱 Biophytis 網站上可用的2023年財務報告中的“公司即將面臨的風險與不確定性”部分以及20-F表格中的“風險因素”部分以及提交給美國證券交易委員會（SEC）的其他表格。我們沒有義務公開更新或審查任何前瞻性聲明，無論是因爲新的信息，未來的發展還是其他情況，除非法律要求。
Biophytis contacts
Biophytis聯繫方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投資者關係
Nicolas Fellmann，CFO
Investors@biophytis.com
Media
Antoine Denry:
antoine.denry@taddeo.fr
+33 6 18 07 83 27
媒體
Antoine Denry:
antoine.denry@taddeo.fr
+33 6 18 07 83 27
Nizar Berrada:
nizar.berrada@taddeo.fr
+33 6 38 31 90 50
Nizar Berrada:
nizar.berrada@taddeo.fr
+33 6 38 31 90 50
SOURCE: Biophytis
來源：Biophytis
譯文內容由第三人軟體翻譯。